



ABN 53 075 582 740

ASX ANNOUNCEMENT
20 November 2019

PLANNED RECRUITMENT OF NEW CEO
EXTENSION OF EXECUTIVE CHAIRMAN CONTRACT IN THE INTERIM

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company announced today at its Annual General Meeting that Dr Errol De Souza will continue in the role of Executive Chairman from 21 November 2019 for a period of 6 months, pending the recruitment of a new CEO.

The Company is appointing a recruitment firm to identify suitable candidates for the role of CEO.

Dr De Souza's appointment to 21 June 2020 is on the same terms and conditions previously advised to the market, a summary of which is as follows:

Material Terms of Extended Consultancy Agreement – Executive Chairman

In accordance with ASX Listing Rule 3.16.4, Bionomics makes the following disclosures in respect of the material terms of the Consulting Agreement between the Company and Dr Errol De Souza dated 15 November 2018 (as extended):

Position	Executive Chairman
Commencement Date	21 November 2019
Expiry Date	21 June 2020
Fixed Remuneration	\$18,000 per month, for 10 working days per month
Short Term Incentive (STI)	Not applicable
Long Term Incentive (LTI)	Not applicable
Termination	7 days' notice by either party

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au